Nonalcoholic fatty liver disease (NAFLD) and its inflammatory and often progressive subtype
nonalcoholic steatohepatitis (NASH) are becoming the leading cause of liver-related …

High levels of cholesterol are generally considered to be associated with atherosclerosis. In
the past two decades, however, a number of studies have shown that excess cholesterol …

It is widely known that the liver is a central organ in lipogenesis, gluconeogenesis and
cholesterol metabolism. However, over the last decades, a variety of pathological conditions …

The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and NAFLD‐related
cirrhosis in the United States and globally highlights the need to better understand the …

Lipotoxicity drives the development of progressive hepatic inflammation and fibrosis in a
subgroup of patients with nonalcoholic fatty liver disease (NAFLD), causing nonalcoholic …

CD36/FAT (fatty acid translocase) is associated with human and murine nonalcoholic fatty
liver disease, but it has been unclear whether it is simply a marker or whether it directly …

Significance: Nonalcoholic fatty liver disease (NAFLD), characterized by liver triacylglycerol
build-up, has been growing in the global world in concert with the raised prevalence of …

Triggering receptor expressed on myeloid cells 2 (TREM2) is a single-pass transmembrane
immune receptor that is mainly expressed on microglia in the brain and macrophages in the …

Nonalcoholic steatohepatitis (NASH) is a key step in the progression of nonalcoholic fatty
liver (NAFL) to cirrhosis. However, the molecular mechanisms of the NAFL-to-NASH …

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and
a major cause of liver cirrhosis and hepatocellular carcinoma. NAFLD is intimately linked …